Johnson & Johnson Unveils IMAAVY Data That Could Expand Early gMG Use

Johnson & Johnson (NYSE:JNJ) presented new clinical data for IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis (gMG) at the European Academy of Neurology 2026 Congress. The data focus on earlier use of IMAAVY in the gMG treatment pathway and outcomes for patients with less severe symptoms.

The Product

IMAAVY is a monoclonal antibody targeting the FcRn receptor, reducing levels of disease-causing IgG antibodies. The new data show potential efficacy in patients with mild symptoms, which could expand its use to earlier stages of gMG.

Pricing and Availability

Pricing and availability details have not been announced, but the company is expected to seek expanded regulatory approval based on these data.

Competition

IMAAVY competes with other gMG drugs such as Argenx's Vyvgart (efgartigimod) and UCB's rozanolixizumab. IMAAVY's differentiating features include flexible monthly dosing and potential for earlier use.

Potential Impact on the Company

The new data could strengthen Johnson & Johnson's position in the rare disease market, particularly if early-use approval is granted. The PETUNIA study, tracking IMAAVY safety in pregnancy, may further broaden the patient population.